

25100364D

SENATE BILL NO. 1081

Offered January 8, 2025

Prefiled January 7, 2025

A BILL to amend and reenact §§ 54.1-3222, 54.1-3223, 54.1-3301, and 54.1-3303 of the Code of Virginia, relating to Optometry; TPA-Formulary; TPA-Formulary Committee; dissolution.

Patron—Hashmi

Referred to Committee on Education and Health

Be it enacted by the General Assembly of Virginia:

1. That §§ 54.1-3222, 54.1-3223, 54.1-3301, and 54.1-3303 of the Code of Virginia are amended and reenacted as follows:

§ 54.1-3222. TPA certification; certification for treatment of diseases or abnormal conditions with therapeutic pharmaceutical agents (TPAs).

TPA certification shall enable an optometrist to prescribe and administer, within his scope of practice, Schedule II controlled substances consisting of hydrocodone in combination with acetaminophen and Schedules III through VI controlled substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) to treat diseases and abnormal conditions of the human eye and its adnexa as determined by the Board, within the following conditions:

1. Treatment with oral therapeutic pharmaceutical agents shall be limited to (i) analgesics included on Schedule II controlled substances as defined in § 54.1-3448 of the Drug Control Act (§ 54.1-3400 et seq.) consisting of hydrocodone in combination with acetaminophen, and analgesics included on Schedules III through VI, as defined in §§ 54.1-3450 and 54.1-3455 of the Drug Control Act, which are appropriate to alleviate ocular pain and (ii) other Schedule VI controlled substances as defined in § 54.1-3455 of the Drug Control Act appropriate to treat diseases and abnormal conditions of the human eye and its adnexa.

2. Therapeutic pharmaceutical agents shall include topically applied Schedule VI drugs as defined in § 54.1-3455 of the Drug Control Act (§ 54.1-3400 et seq.).

3. Administration of therapeutic pharmaceutical agents by injection shall be limited to the treatment of chalazia by means of injection of a steroid included in Schedule VI controlled substances as set forth in § 54.1-3455 of the Drug Control Act (§ 54.1-3400 et seq.). A TPA-certified optometrist shall provide written evidence to the Board that he has completed a didactic and clinical training course provided by an accredited school or college of optometry that includes training in administration of TPAs by injection prior to administering TPAs by injection pursuant to this subdivision.

4. Treatment of angle closure glaucoma shall be limited to initiation of immediate emergency care.

5. Treatment of infantile or congenital glaucoma shall be prohibited.

6. Treatment through surgery or other invasive modalities shall not be permitted, except as provided in subdivision 3 or for treatment of emergency cases of anaphylactic shock with intramuscular epinephrine.

7. Entities permitted or licensed by the Board of Pharmacy to distribute or dispense drugs, including, but not limited to, wholesale distributors and pharmacists, shall be authorized to supply TPA-certified optometrists with those therapeutic pharmaceutical agents specified by the Board on the TPA Formulary.

§ 54.1-3223. Regulations relating to therapeutic pharmaceutical agents.

~~A.~~ The Board shall promulgate such regulations governing the treatment of diseases and abnormal conditions of the human eye and its adnexa with therapeutic pharmaceutical agents by TPA-certified optometrists as are reasonable and necessary to ensure an appropriate standard of medical care for patients, including, but not limited to, determinations of the diseases and abnormal conditions of the human eye and its adnexa that may be treated by TPA-certified optometrists; and treatment guidelines; and the drugs specified on the TPA Formulary.

~~In order to maintain a current and appropriate list of therapeutic pharmaceuticals on the TPA Formulary, current and appropriate treatment guidelines, and current and appropriate determinations of diseases and abnormal conditions of the eye and its adnexa that may be treated by TPA-certified optometrists, the Board may, from time to time, amend such regulations. Such regulations and amendments thereto shall be exempt from the requirements of the Administrative Process Act (§ 2.2-4000 et seq.), except to any extent that they may be specifically made subject to §§ 2.2-4024, 2.2-4030, and 2.2-4031; the Board's regulations shall, however, comply with § 2.2-4103 of the Virginia Register Act (§ 2.2-4100 et seq.). The Board shall, however, conduct a public hearing prior to making amendments to the TPA Formulary, the treatment guidelines or the determinations of diseases and abnormal conditions of the eye and its adnexa that may be treated by TPA-certified optometrists. Thirty days prior to conducting such hearing, the Board shall give written notice by mail or electronic means of the date, time, and place of the hearing to all currently~~

INTRODUCED

SB1081

1/28/25 10:22

59 TPA-certified optometrists and any other persons requesting to be notified of the hearings and publish notice
 60 of its intention to amend the ~~list regulations~~ in the Virginia Register of Regulations. During the public
 61 hearing, interested parties shall be given reasonable opportunity to be heard and present information prior to
 62 final adoption of any TPA-Formulary amendments. Proposed and final amendments of the ~~list~~ shall also be
 63 published, pursuant to § 2.2-4031, in the Virginia Register of Regulations. ~~Final amendments to the~~
 64 ~~TPA-Formulary shall become effective upon filing with the Registrar of Regulations. The TPA-Formulary~~
 65 ~~shall be the inclusive list of the therapeutic pharmaceutical agents that a TPA-certified optometrist may~~
 66 ~~prescribe.~~

67 B. To assist in the specification of the TPA-Formulary, there shall be a seven-member TPA-Formulary
 68 Committee, as follows: three Virginia TPA-certified optometrists to be appointed by the Board of Optometry;
 69 one pharmacist appointed by the Board of Pharmacy from among its licensees; two ophthalmologists
 70 appointed by the Board of Medicine from among its licensees; and the chairman who shall be appointed by
 71 the Board of Optometry from among its members. The ophthalmologists appointed by the Board of Medicine
 72 shall have demonstrated, through professional experience, knowledge of the optometric profession. In the
 73 event the Board of Pharmacy or the Board of Medicine fails to make appointments to the TPA-Formulary
 74 Committee within 30 days following the Board of Optometry's requesting such appointments, or within 30
 75 days following any subsequent vacancy, the Board of Optometry shall appoint such members.

76 The TPA-Formulary Committee shall recommend to the Board those therapeutic pharmaceutical agents to
 77 be included on the TPA-Formulary for the treatment of diseases and abnormal conditions of the eye and its
 78 adnexa by TPA-certified optometrists.

79 **§ 54.1-3301. Exceptions.**

80 This chapter shall not be construed to:

81 1. Interfere with any legally qualified practitioner of dentistry, or veterinary medicine or any physician
 82 acting on behalf of the Virginia Department of Health or local health departments, in the compounding of his
 83 prescriptions or the purchase and possession of drugs as he may require;

84 2. Prevent any legally qualified practitioner of dentistry, or veterinary medicine or any prescriber, as
 85 defined in § 54.1-3401, acting on behalf of the Virginia Department of Health or local health departments,
 86 from administering or supplying to his patients the medicines that he deems proper under the conditions of §
 87 54.1-3303 or from causing drugs to be administered or dispensed pursuant to §§ 32.1-42.1 and 54.1-3408,
 88 except that a veterinarian shall only be authorized to dispense a compounded drug, distributed from a
 89 pharmacy, when (i) the animal is his own patient, (ii) the animal is a companion animal as defined in
 90 regulations promulgated by the Board of Veterinary Medicine, (iii) the quantity dispensed is no more than a
 91 seven-day supply, (iv) the compounded drug is for the treatment of an emergency condition, and (v) timely
 92 access to a compounding pharmacy is not available, as determined by the prescribing veterinarian;

93 3. Prohibit the sale by merchants and retail dealers of proprietary medicines as defined in Chapter 34 (§
 94 54.1-3400 et seq.) of this title;

95 4. Prevent the operation of automated drug dispensing systems in hospitals pursuant to Chapter 34 (§
 96 54.1-3400 et seq.) of this title;

97 5. Prohibit the employment of ancillary personnel to assist a pharmacist as provided in the regulations of
 98 the Board;

99 6. Interfere with any legally qualified practitioner of medicine, osteopathy, or podiatry from purchasing,
 100 possessing or administering controlled substances to his own patients or providing controlled substances to
 101 his own patients in a bona fide medical emergency or providing manufacturers' professional samples to his
 102 own patients;

103 7. Interfere with any legally qualified practitioner of optometry, certified or licensed to use diagnostic
 104 pharmaceutical agents, from purchasing, possessing or administering those controlled substances as specified
 105 in § 54.1-3221 or interfere with any legally qualified practitioner of optometry certified to prescribe
 106 therapeutic pharmaceutical agents from purchasing, possessing, or administering to his own patients those
 107 controlled substances as specified in § 54.1-3222 ~~and the TPA formulary~~, providing manufacturers' samples
 108 of these drugs to his own patients, or dispensing, administering, or selling ophthalmic devices as authorized
 109 in § 54.1-3204;

110 8. Interfere with any physician assistant with prescriptive authority receiving and dispensing to his own
 111 patients manufacturers' professional samples of controlled substances and devices that he is authorized, in
 112 compliance with the provisions of § 54.1-2952.1, to prescribe according to his practice setting and a written
 113 agreement with a physician or podiatrist;

114 9. Interfere with any licensed advanced practice registered nurse with prescriptive authority receiving and
 115 dispensing to his own patients manufacturers' professional samples of controlled substances and devices that
 116 he is authorized, in compliance with the provisions of § 54.1-2957.01, to prescribe;

117 10. Interfere with any legally qualified practitioner of medicine or osteopathy participating in an indigent
 118 patient program offered by a pharmaceutical manufacturer in which the practitioner sends a prescription for
 119 one of his own patients to the manufacturer, and the manufacturer donates a stock bottle of the prescription

120 drug ordered at no cost to the practitioner or patient. The practitioner may dispense such medication at no
 121 cost to the patient without holding a license to dispense from the Board of Pharmacy. However, the container
 122 in which the drug is dispensed shall be labeled in accordance with the requirements of § 54.1-3410, and,
 123 unless directed otherwise by the practitioner or the patient, shall meet standards for special packaging as set
 124 forth in § 54.1-3426 and Board of Pharmacy regulations. In lieu of dispensing directly to the patient, a
 125 practitioner may transfer the donated drug with a valid prescription to a pharmacy for dispensing to the
 126 patient. The practitioner or pharmacy participating in the program shall not use the donated drug for any
 127 purpose other than dispensing to the patient for whom it was originally donated, except as authorized by the
 128 donating manufacturer for another patient meeting that manufacturer's requirements for the indigent patient
 129 program. Neither the practitioner nor the pharmacy shall charge the patient for any medication provided
 130 through a manufacturer's indigent patient program pursuant to this subdivision. A participating pharmacy,
 131 including a pharmacy participating in bulk donation programs, may charge a reasonable dispensing or
 132 administrative fee to offset the cost of dispensing, not to exceed the actual costs of such dispensing. However,
 133 if the patient is unable to pay such fee, the dispensing or administrative fee shall be waived;

134 11. Interfere with any legally qualified practitioner of medicine or osteopathy from providing controlled
 135 substances to his own patients in a free clinic without charge when such controlled substances are donated by
 136 an entity other than a pharmaceutical manufacturer as authorized by subdivision 10. The practitioner shall
 137 first obtain a controlled substances registration from the Board and shall comply with the labeling and
 138 packaging requirements of this chapter and the Board's regulations; or

139 12. Prevent any pharmacist from providing free health care to an underserved population in Virginia who
 140 (i) does not regularly practice pharmacy in Virginia, (ii) holds a current valid license or certificate to practice
 141 pharmacy in another state, territory, district or possession of the United States, (iii) volunteers to provide free
 142 health care to an underserved area of this Commonwealth under the auspices of a publicly supported all
 143 volunteer, nonprofit organization that sponsors the provision of health care to populations of underserved
 144 people, (iv) files a copy of the license or certificate issued in such other jurisdiction with the Board, (v)
 145 notifies the Board at least five business days prior to the voluntary provision of services of the dates and
 146 location of such service, and (vi) acknowledges, in writing, that such licensure exemption shall only be valid,
 147 in compliance with the Board's regulations, during the limited period that such free health care is made
 148 available through the volunteer, nonprofit organization on the dates and at the location filed with the Board.
 149 The Board may deny the right to practice in Virginia to any pharmacist whose license has been previously
 150 suspended or revoked, who has been convicted of a felony or who is otherwise found to be in violation of
 151 applicable laws or regulations. However, the Board shall allow a pharmacist who meets the above criteria to
 152 provide volunteer services without prior notice for a period of up to three days, provided the nonprofit
 153 organization verifies that the practitioner has a valid, unrestricted license in another state.

154 This section shall not be construed as exempting any person from the licensure, registration, permitting
 155 and record keeping requirements of this chapter or Chapter 34 of this title.

156 **§ 54.1-3303. Prescriptions to be issued and drugs to be dispensed for medical or therapeutic**
 157 **purposes only.**

158 A. A prescription for a controlled substance may be issued only by a practitioner of medicine, osteopathy,
 159 podiatry, dentistry or veterinary medicine who is authorized to prescribe controlled substances, a licensed
 160 advanced practice registered nurse pursuant to § 54.1-2957.01, a licensed certified midwife pursuant to §
 161 54.1-2957.04, a licensed physician assistant pursuant to § 54.1-2952.1, or a TPA-certified optometrist
 162 pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32.

163 B. A prescription shall be issued only to persons or animals with whom the practitioner has a bona fide
 164 practitioner-patient relationship or veterinarian-client-patient relationship. If a practitioner is providing
 165 expedited partner therapy consistent with the recommendations of the Centers for Disease Control and
 166 Prevention, then a bona fide practitioner-patient relationship shall not be required.

167 A bona fide practitioner-patient relationship shall exist if the practitioner has (i) obtained or caused to be
 168 obtained a medical or drug history of the patient; (ii) provided information to the patient about the benefits
 169 and risks of the drug being prescribed; (iii) performed or caused to be performed an appropriate examination
 170 of the patient, either physically or by the use of instrumentation and diagnostic equipment through which
 171 images and medical records may be transmitted electronically; and (iv) initiated additional interventions and
 172 follow-up care, if necessary, especially if a prescribed drug may have serious side effects. Except in cases
 173 involving a medical emergency, the examination required pursuant to clause (iii) shall be performed by the
 174 practitioner prescribing the controlled substance, a practitioner who practices in the same group as the
 175 practitioner prescribing the controlled substance, or a consulting practitioner.

176 A practitioner who has established a bona fide practitioner-patient relationship with a patient in
 177 accordance with the provisions of this subsection may prescribe Schedule II through VI controlled substances
 178 to that patient.

179 A practitioner who has established a bona fide practitioner-patient relationship with a patient in
 180 accordance with the provisions of this subsection may prescribe Schedule II through VI controlled substances

181 to that patient via telemedicine if such prescribing is in compliance with federal requirements for the practice
182 of telemedicine and, in the case of the prescribing of a Schedule II through V controlled substance, the
183 prescriber maintains a practice at a physical location in the Commonwealth or is able to make appropriate
184 referral of patients to a licensed practitioner located in the Commonwealth in order to ensure an in-person
185 examination of the patient when required by the standard of care.

186 A prescriber may establish a bona fide practitioner-patient relationship for the purpose of prescribing
187 Schedule II through VI controlled substances by an examination through face-to-face interactive, two-way,
188 real-time communications services or store-and-forward technologies when all of the following conditions
189 are met: (a) the patient has provided a medical history that is available for review by the prescriber; (b) the
190 prescriber obtains an updated medical history at the time of prescribing; (c) the prescriber makes a diagnosis
191 at the time of prescribing; (d) the prescriber conforms to the standard of care expected of in-person care as
192 appropriate to the patient's age and presenting condition, including when the standard of care requires the use
193 of diagnostic testing and performance of a physical examination, which may be carried out through the use of
194 peripheral devices appropriate to the patient's condition; (e) the prescriber is actively licensed in the
195 Commonwealth and authorized to prescribe; (f) if the patient is a member or enrollee of a health plan or
196 carrier, the prescriber has been credentialed by the health plan or carrier as a participating provider and the
197 diagnosing and prescribing meets the qualifications for reimbursement by the health plan or carrier pursuant
198 to § 38.2-3418.16; (g) upon request, the prescriber provides patient records in a timely manner in accordance
199 with the provisions of § 32.1-127.1:03 and all other state and federal laws and regulations; (h) the
200 establishment of a bona fide practitioner-patient relationship via telemedicine is consistent with the standard
201 of care, and the standard of care does not require an in-person examination for the purpose of diagnosis; and
202 (i) the establishment of a bona fide practitioner patient relationship via telemedicine is consistent with federal
203 law and regulations and any waiver thereof. Nothing in this paragraph shall apply to (1) a prescriber
204 providing on-call coverage per an agreement with another prescriber or his prescriber's professional entity or
205 employer; (2) a prescriber consulting with another prescriber regarding a patient's care; or (3) orders of
206 prescribers for hospital out-patients or in-patients.

207 For purposes of this section, a bona fide veterinarian-client-patient relationship is one in which a
208 veterinarian, another veterinarian within the group in which he practices, or a veterinarian with whom he is
209 consulting has assumed the responsibility for making medical judgments regarding the health of and
210 providing medical treatment to an animal as defined in § 3.2-6500, other than an equine as defined in §
211 3.2-6200, a group of agricultural animals as defined in § 3.2-6500, or bees as defined in § 3.2-4400, and a
212 client who is the owner or other caretaker of the animal, group of agricultural animals, or bees has consented
213 to such treatment and agreed to follow the instructions of the veterinarian. Evidence that a veterinarian has
214 assumed responsibility for making medical judgments regarding the health of and providing medical
215 treatment to an animal, group of agricultural animals, or bees shall include evidence that the veterinarian (A)
216 has sufficient knowledge of the animal, group of agricultural animals, or bees to provide a general or
217 preliminary diagnosis of the medical condition of the animal, group of agricultural animals, or bees; (B) has
218 made an examination of the animal, group of agricultural animals, or bees, either physically or by the use of
219 instrumentation and diagnostic equipment through which images and medical records may be transmitted
220 electronically or has become familiar with the care and keeping of that species of animal or bee on the
221 premises of the client, including other premises within the same operation or production system of the client,
222 through medically appropriate and timely visits to the premises at which the animal, group of agricultural
223 animals, or bees are kept; and (C) is available to provide follow-up care.

224 C. A prescription shall only be issued for a medicinal or therapeutic purpose in the usual course of
225 treatment or for authorized research. A prescription not issued in the usual course of treatment or for
226 authorized research is not a valid prescription. A practitioner who prescribes any controlled substance with
227 the knowledge that the controlled substance will be used otherwise than for medicinal or therapeutic purposes
228 shall be subject to the criminal penalties provided in § 18.2-248 for violations of the provisions of law
229 relating to the distribution or possession of controlled substances.

230 D. No prescription shall be filled unless a bona fide practitioner-patient-pharmacist relationship exists. A
231 bona fide practitioner-patient-pharmacist relationship shall exist in cases in which a practitioner prescribes,
232 and a pharmacist dispenses, controlled substances in good faith to a patient for a medicinal or therapeutic
233 purpose within the course of his professional practice.

234 In cases in which it is not clear to a pharmacist that a bona fide practitioner-patient relationship exists
235 between a prescriber and a patient, a pharmacist shall contact the prescribing practitioner or his agent and
236 verify the identity of the patient and name and quantity of the drug prescribed.

237 Any person knowingly filling an invalid prescription shall be subject to the criminal penalties provided in
238 § 18.2-248 for violations of the provisions of law relating to the sale, distribution or possession of controlled
239 substances.

240 E. Notwithstanding any provision of law to the contrary and consistent with recommendations of the
241 Centers for Disease Control and Prevention or the Department of Health, a practitioner may prescribe

242 Schedule VI antibiotics and antiviral agents to other persons in close contact with a diagnosed patient when
243 (i) the practitioner meets all requirements of a bona fide practitioner-patient relationship, as defined in
244 subsection B, with the diagnosed patient and (ii) in the practitioner's professional judgment, the practitioner
245 deems there is urgency to begin treatment to prevent the transmission of a communicable disease. In cases in
246 which the practitioner is an employee of or contracted by the Department of Health or a local health
247 department, the bona fide practitioner-patient relationship with the diagnosed patient, as required by clause
248 (i), shall not be required.

249 F. A pharmacist may dispense a controlled substance pursuant to a prescription of an out-of-state
250 practitioner of medicine, osteopathy, podiatry, dentistry, optometry, or veterinary medicine, an advanced
251 practice registered nurse, or a physician assistant authorized to issue such prescription if the prescription
252 complies with the requirements of this chapter and the Drug Control Act (§ 54.1-3400 et seq.).

253 G. A licensed advanced practice registered nurse who is authorized to prescribe controlled substances
254 pursuant to § 54.1-2957.01 may issue prescriptions or provide manufacturers' professional samples for
255 controlled substances and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to
256 his patient for a medicinal or therapeutic purpose within the scope of his professional practice.

257 H. A licensed physician assistant who is authorized to prescribe controlled substances pursuant to §
258 54.1-2952.1 may issue prescriptions or provide manufacturers' professional samples for controlled substances
259 and devices as set forth in the Drug Control Act (§ 54.1-3400 et seq.) in good faith to his patient for a
260 medicinal or therapeutic purpose within the scope of his professional practice.

261 I. A TPA-certified optometrist who is authorized to prescribe controlled substances pursuant to Article 5
262 (§ 54.1-3222 et seq.) of Chapter 32 may issue prescriptions in good faith or provide manufacturers'
263 professional samples to his patients for medicinal or therapeutic purposes within the scope of his professional
264 practice for the drugs specified on the TPA-Formulary, established pursuant to § 54.1-3223, which shall be
265 limited to (i) analgesics included on Schedule II controlled substances as defined in § 54.1-3448 of the Drug
266 Control Act (§ 54.1-3400 et seq.) consisting of hydrocodone in combination with acetaminophen; (ii) oral
267 analgesics included in Schedules III through VI, as defined in §§ 54.1-3450 and 54.1-3455 of the Drug
268 Control Act (§ 54.1-3400 et seq.), which are appropriate to relieve ocular pain; (iii) other oral Schedule VI
269 controlled substances, as defined in § 54.1-3455 of the Drug Control Act, appropriate to treat diseases and
270 abnormal conditions of the human eye and its adnexa; (iv) topically applied Schedule VI drugs, as defined in
271 § 54.1-3455 of the Drug Control Act; and (v) intramuscular administration of epinephrine for treatment of
272 emergency cases of anaphylactic shock.

273 J. The requirement for a bona fide practitioner-patient relationship shall be deemed to be satisfied by a
274 member or committee of a hospital's medical staff when approving a standing order or protocol for the
275 administration of influenza vaccinations and pneumococcal vaccinations in a hospital in compliance with §
276 32.1-126.4.

277 K. Notwithstanding any other provision of law, a prescriber may authorize a registered nurse or licensed
278 practical nurse to approve additional refills of a prescribed drug for no more than 90 consecutive days,
279 provided that (i) the drug is classified as a Schedule VI drug; (ii) there are no changes in the prescribed drug,
280 strength, or dosage; (iii) the prescriber has a current written protocol, accessible by the nurse, that identifies
281 the conditions under which the nurse may approve additional refills; and (iv) the nurse documents in the
282 patient's chart any refills authorized for a specific patient pursuant to the protocol and the additional refills are
283 transmitted to a pharmacist in accordance with the allowances for an authorized agent to transmit a
284 prescription orally or by facsimile pursuant to subsection C of § 54.1-3408.01 and regulations of the Board.